CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple MyelomaSimon J. Harrison, Piers Blombery, Arnob Banerjee et al.|Blood|2023Cited by 99
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Imtiaz A. Samjoo, Saad Z. Usmani et al.|Current Medical Research and Opinion|2022Cited by 25
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma after 1-3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 CARTITUDE-4 TrialM Hasib Sidiqi, Kwee Yong, Paolo Corradini et al.|Blood|2023Cited by 4
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 TrialM Hasib Sidiqi, Kwee Yong, Paolo Corradini et al.|Transplantation and Cellular Therapy|2024Cited by 1